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For the hydrated proton-transfer compound 6-chloro-9-[(4-
diethylammonio-2-methylbutyl)amino]-2-methoxyacridinium
3-carboxylato-4-hydroxybenzenesulfonate dihydrate, C23H32-
ClN3O
2+C7H4O6S22H2O, (I), the conformational features,
specifically those of the extended side chain at the 9-position
of the acridine parent, have been compared with those of
quinacrinium dichloride dihydrate (the drug atabrine or
mepacrine). Racemic compound (I) has a three-dimensional
hydrogen-bonded framework structure similar to atabrine but
also involves the water molecules and both the carboxylate
and sulfonate groups of the anion in structure extension. The
comparable conformational features found in this uncommon
derivative of quinacrine indicate that (I) has potential as a
possible pharmaceutical substitute for atabrine.
Comment
Quinacrine [N0-(6-chloro-2-methoxyacridin-9-yl)-N,N-diethyl-
pentane-1,4-diamine] was first synthesized in 1931 at Bayer–
I. G. Farben (Mietzsch & Mauss, 1934) and, as the dihydro-
chloride dihydrate (atabrine or mepacrine), introduced as a
drug which was the first alternative to quinine for the treat-
ment of malaria (Mauss & Mietzsch, 1934) and other parasite-
borne diseases (e.g. Chaga’s disease, giardiasis). Its use in the
treatment of malaria has largely been superceded by chloro-
quine, which has fewer of the undesirable adverse physiolo-
gical side effects of quinacrine, e.g. aplastic anaemia and
hyperpigmentation (Wilson et al., 1991). However, its more
recent experimental and sometimes controversial uses include
the possible treatment of Creutzfeldt–Jacob disease, where it
has been found to inhibit the accumulation of pathogenic
prion protein in cultured neuroblastoma cells (Doh-Ura et al.,
2000), and for nonsurgical female sterilization (Zipper et al.,
1980). The crystal structure of the Trypanosoma cruzi trypa-
nothione reducatase (TR) complex with quinacrine (Jacobi et
al., 1996) showed that specific sites on the acridine ring system
(the hetero N, C2 methoxy O and C6 chloro substituent
groups), as well as the two amino groups of the C9 substituent
side chain, are fixed at active sites of the TR enzyme.
The crystal structure of racemic atabrine (quinacrine
dihydrochloride dihydrate; Courseille et al., 1973) showed the
molecule to be protonated at the N atom of the acridine ring
and at the tertiary terminal N atom of the C9 side chain. In
addition, the acridine ring systems showed interactive –
stacking effects. Considering the difficulty in obtaining good
crystals of atabrine, we have prepared the salts of this base
with the strong aromatic organic acids 3,5-dinitrosalicylic acid
(DNSA) and 3-carboxy-4-hydroxybenzenesulfonic acid
(5-sulfosalicylic acid, 5-SSA) for the purpose of crystallo-
graphic examination. This approach has been used previously
by us and other research groups with reasonable success since
these acids, particularly when used in their anionic forms, are
recognized as useful synthons for molecular assembly
achieved through hydrogen-bonding interactions involving
potentially all interactive substituent functional groups. The
method allows the structures of difficult-to-crystallize Lewis
base compounds, such as many pharmaceuticals, to be deter-
mined.
The crystal structures have been reported of the 1:1 salts of
5-SSA with theophylline (a monohydrate; Madarasz et al.,
2002), trimethoprim (a dihydrate; Raj et al., 2003), and pyri-
methamine (Hemamalini et al., 2005) and brucine (Smith,
Wermuth, Healy & White, 2006) (both anhydrates). With
DNSA, the structures of 1:1 anhydrous salts with both brucine
(Smith, Wermuth, Healy & White, 2006) and strychnine
(Smith et al., 2005) are also known. With the 5-SSA anions
formed in the reaction of the acid with Lewis bases, all of the
substituent groups provide hydrogen-bonding donor or
acceptor atoms with potential for both primary and secondary
structure extension. In some examples, particularly those salts
with polycyclic heteroaromatic amines (Smith, Wermuth &
White, 2004), the structures feature anion–anion or anion–
cation – interactions. We obtained good crystals of the
atabrine salt with 5-SSA from an aqueous ethanol solution but
not with the DNSA salt prepared under similar conditions.
The crystal structure of the 5-SSA salt reported here is that
of racemic quinacrinium 5-sulfosalicylate dihydrate, (I). The
quinacrine molecule is protonated at both the acridine N
(N10) and the terminal tertiary diethylamino N atom (N141),
while generating a 5-SSA dianion by deprotonation of both
the sulfonic acid and carboxylic acid groups. Dianionic 5-SSA
anions are not common among the known structures in the
crystallographic literature but some are known, e.g. the salts
organic compounds
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with guanidine (Smith, Wermuth & Healy, 2004), benzylamine
(Smith, Wermuth & Healy, 2006), 2-aminopyridine (Yang &
Qu, 2006) and piperazine (Su & Li, 2007).
In the asymmetric unit of (I) (Fig. 1), the dication has
primary hydrogen-bonding interactions involving the proton-
ated tertiary amine N atom (N141) and one of the water
molecules (O1W), as well as the secondary amine N atom
(N91) and the second water molecule (O2W), while the H
atom of the acridinium N atom is involved in secondary
interactions with a carboxyl group of the 5-SSA dianion [cyclic
three-centre asymmetric, graph set R21(4) (Etter et al., 1990)]
(Table 1). Other secondary inter-species hydrogen bonds
generate a three-dimensional framework structure (Fig. 2),
which is also found in the structure of quinacrinium chloride
dihydrate (Courseille et al., 1973). However, in that structure,
the acridinium H atom has a primary interaction with one of
the chloride anions, which is in turn associated with the solvent
water molecules in structure extension. Conformationally the
two structures are similar, with the C91 side chain adopting a
comparable perpendicular attitude with respect to the acridine
ring (Table 2), which is also the case in the structures of other
C9 extended-chain-substituted 6-chloro-2-methoxyacridines,
e.g. in the antitumour acridine analogues (Berman & Glusker,
1972; Carrell, 1972; Glusker et al., 1972). The only major
difference between (I) and the dichloride is found, not
unexpectedly, within the terminal diethylamino group. Also, in
(I), there are no cation–cation or cation–anion aromatic ring
– interactions, which are present in the structure of the
hydrochloride [minimum centroid separation of the inversion-
related six-membered rings N10/C9/C12–C13 and (C5–C8/
C13/C14)ii = 4.1834 (13) A˚; symmetry code: (ii) xþ 12;yþ 32;
zþ 12].
With the 5-SSA anion species for (I), similar structural and
conformational features to those previously observed (Smith,
Wermuth & White, 2004) are found. The usual intramolecular
phenol–carboxyl O—H  O hydrogen bond is found [series
range 2.598 (3)–2.625 (2) A˚], giving essentially coplanarity of
the carboxyl group and the benzene ring [torsion angle C2—
C1—C7—O71 = 175.0 (2)]. In addition, the common arom-
atic–sulfonate C6A—H6A  O52A interaction [2.879 (2) A˚] is
present. It may be concluded that the chemically stable and
structurally similar 5-sulfosalicylate salt of quinacrine, (I),
could be considered a possible alternative to atabrine as a
drug.
Experimental
The title compound was synthesized by heating together 1 mmol
quantities of quinacrium dichloride dihydrate (atabrine or mepa-
crine) (O’Neil, 2001) and 3-carboxy-4-hydroxybenzenesulfonic acid
(5-sulfosalicylic acid = 5-SSA) in 50% ethanol–water (50 ml) under
reflux for 10 min. After concentration to ca 30 ml, partial room-
temperature evaporation of the hot-filtered solution gave yellow
block-shaped crystals of (I) (m.p. 523 K).
Crystal data
C23H32ClN3O
2+C7H4O6S22H2O
Mr = 654.17
Monoclinic, P21=n
a = 10.1753 (3) A˚
b = 30.8461 (7) A˚
c = 10.3671 (2) A˚
 = 99.966 (3)
V = 3204.81 (14) A˚3
Z = 4
Mo K radiation
 = 0.24 mm1
T = 297 (2) K
0.20  0.20  0.15 mm
Data collection
Oxford Diffraction Gemini-S Ultra
CCD detector diffractometer
Absorption correction: multi-scan
(SADABS; Sheldrick, 1996)
Tmin = 0.906, Tmax = 0.960
29865 measured reflections
5455 independent reflections
3568 reflections with I > 2(I)
Rint = 0.049
organic compounds
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Figure 1
The molecular conformation and atom-numbering scheme for the
quinacrine dication, the 5-sulfosalicylate dianion and the two solvent
water molecules in (I). Displacement ellipsoids are drawn at the 30%
probability level and H atoms are shown as small spheres of arbitrary size.
Inter-species hydrogen-bonding associations are shown as dashed lines.
Figure 2
Hydrogen-bonding extensions in the structure of (I), shown in a partial
view down the approximate c axial direction. [Symmetry code: (v) x  12,y + 32, z + 12; for other symmetry codes, see Table 1.]
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Refinement
R[F 2 > 2(F 2)] = 0.040
wR(F 2) = 0.100
S = 0.99
5455 reflections
433 parameters
H atoms treated by a mixture of
independent and constrained
refinement
max = 0.26 e A˚
3
min = 0.26 e A˚3
H atoms potentially involved in hydrogen-bonding interactions
(aminium, carboxyl, phenol and water) were located by difference
methods and their positional and isotropic displacement parameters
were refined. Other H atoms were included in the refinement at
calculated positions as riding atoms, with aromatic C—H = 0.93 A˚
and aliphatic C—H = 0.96 or 0.97 A˚, and with Uiso(H) = 1.2Ueq(C).
Data collection: CrysAlis CCD (Oxford Diffraction, 2008); cell
refinement: CrysAlis RED (Oxford Diffraction, 2008); data reduc-
tion: CrysAlis RED; program(s) used to solve structure: SIR92
(Altomare et al., 1994); program(s) used to refine structure:
SHELXL97 (Sheldrick, 2008); molecular graphics: PLATON (Spek,
2003); software used to prepare material for publication: PLATON.
The authors acknowledge financial support from the
Australian Research Council and the School of Physical and
Chemical Sciences of the Queensland University of Tech-
nology.
Supplementary data for this paper are available from the IUCr electronic
archives (Reference: DN3093). Services for accessing these data are
described at the back of the journal.
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Table 1
Hydrogen-bond geometry (A˚, ).
D—H  A D—H H  A D  A D—H  A
O2A—H2A  O72A 0.92 (3) 1.69 (3) 2.554 (2) 156 (3)
N10—H10  O71Ai 0.90 (3) 2.49 (2) 3.178 (2) 134 (2)
N10—H10  O72Ai 0.90 (3) 1.94 (3) 2.825 (3) 168 (2)
N91—H91  O2W 0.90 (2) 2.00 (2) 2.869 (2) 163.6 (19)
N141—H141  O1W 0.91 (2) 1.80 (2) 2.700 (3) 173.3 (19)
O1W—H11W  O71A 0.77 (3) 1.97 (3) 2.740 (3) 179 (3)
O1W—H12W  O51Aii 0.83 (3) 1.95 (3) 2.770 (3) 172 (3)
O2W—H21W  O71Aiii 0.89 (3) 1.88 (3) 2.759 (2) 170 (3)
O2W—H22W  O52Aiv 0.88 (3) 1.87 (3) 2.744 (2) 175 (3)
Symmetry codes: (i) xþ 2;yþ 2;zþ 2; (ii) xþ 12;yþ 32; zþ 12; (iii) x; y; z 1; (iv)
xþ 12;yþ 32; z 12.
Table 2
Comparison of torsion angles () within the C9 side chain for (I) and
quinacrinium dichloride dihydrate, (II) (Courseille et al., 1973).
Torsion angle () (I) (II)
C11—C9—N91—C101 157.06 (19) 174.4 (5)
C9—N91—C101—C111 125.0 (2) 142.9 (6)
N91—C101—C111—C121 62.6 (2) 64.4 (5)
C101—C111—C121—C131 175.79 (16) 172.8 (4)
C111—C121—C131—N141 170.13 (16) 165.3 (4)
C121—C131—N141—C151 163.03 (18) 64.7 (5)
C121—C131—N141—C171 67.9 (2) 66.1 (6)
C131—N141—C151—C161 67.4 (2) 55.7 (8)
C131—N141—C171—C181 175.61 (19) 147.1 (8)
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